who are the key players? And What is the structure of the global Single Cell Analysis Market

The Global Single Cell Analysis Market in terms of revenue was estimated to be worth $3.1 billion in 2021 and is poised to reach $6.3 billion by 2026, growing at a CAGR of 15.1% from 2021 to 2026. Growth in this market is mainly driven by factors such as technological advancements in single-cell analysis products coupled with increasing R&D in the pharmaceutical and biotechnology industries, growing focus on personalized medicine, growth in stem cell research, and the rising prevalence of cancer. However, the high cost of single-cell analysis products is a major factor hampering the growth of the single-cell analysis market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

Browse in-depth TOC on “Single Cell Analysis Market”

257 – Tables

57 – Figures

296 – Pages

Key Player

The global single-cell analysis market is highly consolidated. Key players in the market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck KGAA (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), 10x Genomics (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US), Tecan Group Ltd. (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems, Inc. (Italy), bioMérieux SA (France), Oxford Nanopore Technologies (UK), Cytek Biosciences (US), Corning Incorporated (US), Apogee Flow Systems Ltd. (UK), NanoCellect Biomedical (US), Rarecyte Inc (US), and On-chip Biotechnologies Co., Ltd. (Japan). The key players in this market are increasingly focusing on strategic expansions, partnerships, to expand their manufacturing capabilities and increase market presence.

Single Cell Analysis Market Dynamics

Drivers: Growing prevalence of cancer

One of the most important application areas of single-cell analysis is cancer genomics. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040 from 19.3 million cases and 10 million cancer deaths in 2020. The growth in the prevalence of this disease has resulted in a need to conduct extensive research for diagnosis and treatment; single-cell analysis forms an important part of this research. The analysis of individual cells enables the correct diagnosis of diseases and monitoring of treatment efficacy. Single-cell analysis aids in the enumeration of helper T-cells, determination of DNA content, and monitoring the proliferation of tumor cells in breast cancer and other malignancies.

Restraints: High cost of single-cell analysis products

The cost of research in single-cell biology is high because of the need to maintain high-quality standards (the use of high-grade, expensive products) and comply with the guidelines set by regulatory authorities. However, research and academic laboratories find it difficult to afford such expensive instruments due to budget constraints. In addition, the maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. This is a major factor limiting the adoption of flow cytometers and microfluidic devices in both clinical and research applications.

Opportunities: High growth potential of single-cell sequencing

Single-cell sequencing is considered a powerful tool to identify disease-specific biomarkers to diagnose and monitor the occurrence and progress of a disease and the patient’s response to treatment. As the SCS technology provides extensive details pertaining to genetic mutations, companies are focusing on developing instruments and reagents that are suitable for single-cell sequencers. Considering the high-growth potential of this segment, several advanced SCS instruments are expected to be developed and launched in the market in the coming years.

The consumables segment dominated the single cell analysis market in 2020:

Based on products, the market is segmented into consumables and instruments. Consumables accounted for the largest share of 67.4% of the single-cell analysis market in 2020. The large share of this segment can primarily be attributed to the frequent purchase of these products compared to instruments, which are considered a one-time investment. The wide applications of consumables in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are also expected to drive market growth.

The academic & research laboratories segment accounted for the largest share in 2020

Based on end users, the single cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. In 2020, the academic & research laboratories segment accounted for the largest share of the single-cell analysis market. Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Enquiry Before Buying this Report:https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=171955254

North America was the largest regional market for single-cell analysis in 2020.

North America accounted for the largest share of 44.9% of the global single-cell analysis market in 2020. This market is expected to reach USD 2,520.2 million by 2026 from an estimated USD 1,282.2 million in 2021, at a CAGR of 14.5%. North America’s prominence in this market is mainly attributed to the presence of key market players, coupled with increasing R&D expenditure and federal funding.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=171955254

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/single-cell-analysis-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/single-cell-analysis.asp

Related Reports: